PTGX
Protagonist Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website rotagonist-inc.com
- Employees(FY) 111
- ISIN US74366E1029
Performance
-3.84%
1W
-10.02%
1M
-6.71%
3M
+19.54%
6M
+81.42%
YTD
+108.42%
1Y
Profile
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Technical Analysis of PTGX 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 16:05
- 2024-12-09 03:05
- 2024-12-06 08:39
- 2024-12-06 06:48
- 2024-12-03 19:00
PTGX: Lowering target price to $43.00(Argus Research)
- 2024-11-29 07:05
- 2024-11-29 06:55
Daily – Vickers Top Buyers & Sellers for 11/29/2024(Argus Research)
- 2024-11-29 03:30
- 2024-11-29 03:30
- 2024-11-29 03:29
- 2024-11-26 19:00
PTGX: Raising target price to $47.00(Argus Research)
- 2024-11-22 07:30
- 2024-11-21 18:30
- 2024-11-21 16:05
- 2024-11-21 03:05
- 2024-11-19 07:30
- 2024-11-18 18:30
- 2024-11-18 16:30
- 2024-11-13 12:00
- 2024-11-12 19:00
PTGX: Lowering target price to $45.00(Argus Research)
- 2024-11-07 17:30
- 2024-11-07 16:56
Protagonist Therapeutics: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-07 16:05
- 2024-11-07 03:05
- 2024-11-05 19:00
PTGX: Lowering target price to $48.00(Argus Research)
- 2024-11-05 16:05
- 2024-11-05 08:51
- 2024-11-05 03:05
- 2024-10-28 21:27
- 2024-10-18 06:28
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.